Julie Nielsen Email & Phone Number | Oncology sales representative with a strong record of sales results. 13 years in oncology sales, and 11 years in cardiovascular, psych, and urology sales. Tremendous success in launching new oncology medications including Enhertu (fam-trastuzumab deruxtecan-nxki) an infusion for HER2+ breast cancer and gastric cancer, Rubraca (rucaparib) an oral PARP inhibitor for recurrent ovarian cancer, and Xgeva (denosumab) a monoclonal antibody/targeted therapy for the prevention of bone metastasis, administered as an in-office subcutaneous injection. Extensive experience in calling on oncology accounts and managing a broad range of activities including Part B and D oncology product sales discussions, buy and bill, specialty pharmacies, contracting, access and reimbursement information, total office call.

Julie Nielsen

Oncology sales representative with a strong record of sales results. 13 years in oncology sales, an...
Sioux Falls, South Dakota, United States

*50 free lookup(s) per month.

Julie Nielsen’s Phone Numbers +1 619-933-****

Get JULIE’s Phone Number (For Free)

Social Media

Julie Nielsen’s Location Sioux Falls, South Dakota, United States

Julie Nielsen’s Current Industry Beigene

Julie Nielsen’s Prior Industry Daiichi Sankyo | Clovis Oncology | Amgen | Pfizer

Find accurate emails & phone numbers for over 700M professionals.

Account Manager - Hematology at BeiGene

2022-03-01 00:00:00 - Present

Senior Oncology Territory Manager-ADC Division

2019-09-01 00:00:00 - 2022-03-01 00:00:00

Senior Oncology Territory Manager

2015-09-01 00:00:00 - 2019-09-01 00:00:00

Senior Oncology Sales Representative

2008-09-01 00:00:00 - 2015-09-01 00:00:00

Senior Pharmaceutical Sales Representative

1991-05-01 00:00:00 - 2002-05-01 00:00:00

No Skills Available

No Languages Available

Julie Nielsen is a Oncology sales representative with a strong record of sales results. 13 years in oncology sales, and 11 years in cardiovascular, psych, and urology sales. Tremendous success in launching new oncology medications including Enhertu (fam-trastuzumab deruxtecan-nxki) an infusion for HER2+ breast cancer and gastric cancer, Rubraca (rucaparib) an oral PARP inhibitor for recurrent ovarian cancer, and Xgeva (denosumab) a monoclonal antibody/targeted therapy for the prevention of bone metastasis, administered as an in-office subcutaneous injection. Extensive experience in calling on oncology accounts and managing a broad range of activities including Part B and D oncology product sales discussions, buy and bill, specialty pharmacies, contracting, access and reimbursement information, total office call.